Briacell says MOA validated in cancer journal

Dr. William Williams reports BRIACELL'S BRIA-OTS+™ MECHANISM OF ACTION VALIDATED IN HIGHLY RATED PEER REVIEWED CANCER JOURNAL Briacell Therapeutics Corp. has published the mechanism of action of its next-generation personalized off-the-shelf immunotherapy. This research conducted in collaboration with the National Cancer Institute (NCI), the United States federal government's principal agency for cancer research and training, has been published at JCI Insight, a highly rated peer-reviewed journal dedicated to advancing biomedical research from preclinical discovery through to clinical development. Publication Title: Enhancing dendritic cell cancer vaccine by allogeneic MHC class II expression and Treg depletion (the company's reference 189024-INS-RG-RV-4) "These findings help us better understand the anti-tumour effects of Bria-OTS+ in cancer patients," stated Jay A. Berzofsky, MD, PhD, senior investigator of NCI and co-author of the publication. "The study demonstrated that semi-allogeneic dendritic-cell vaccines recruit alloreactive CD4 T-cell help through mismatched MHC Class II molecules, which in turn strengthens antigen-specific CD8 T-cell responses against tumours." "This publication validates the core design principle behind Bria-OTS+: partial HLA matching enables effective tumour-antigen presentation, while planned HLA mismatching drives robust CD4 helper responses," noted Miguel Lopez-Lago, PhD, Briacell's chief scientific officer. "These findings are directly aligned with Briacell's pipeline of allogeneic immunotherapies, reinforcing our strategy to deliver powerful and scalable treatments for cancer patients." "These data are consistent with the encouraging clinical results we recently reported in our phase 1/2a study in metastatic breast cancer and provide important insights into the mechanism of action of our cellular immunotherapy platform technology," added Dr. William V. Williams, Briacell's president and chief executive officer. About Bria-OTS Bria-OTS is a next-generation, off-the-shelf personalized immunotherapy based on Briacell's lead candidate Bria-IMT currently being evaluated in a phase 1/2a study in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and check point inhibition combination dose expansion cohorts. The company recently progressed into the dose expansion phase. About Briacell Therapeutics Corp. Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. We seek Safe Harbor.